调查GLP-1受体激动剂与情绪障碍之间的关联:一项整合真实世界的数据和门德尔随机化的研究
Xiulan Zheng1, Hao Wang2, Ping Liu3
1School of Pharmacy, Faculty of Medicine, https://ror.org/03jqs2n27Macau University of Science and Technology, Macau SAR, China.
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 没有增加情绪障碍的风险. 遗传分析表明GLP-1RA实际上可以降低焦虑,抑郁和情绪不稳定的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
- 精神病学是一个精神病学.
背景情况:
- 全球GLP-1RA的使用日益增加,需要了解它们对情绪障碍的影响.
- 来自现实世界研究的相互矛盾的发现凸显了对强有力的调查的需要.
- 这项研究探讨了GLP-1RA与情绪/行为结果之间的关联.
研究的目的:
- 综合研究GLP-1RA与情绪/行为结果之间的联系.
- 为了澄清关于GLP-1 RA使用和情绪障碍的相互矛盾的现实世界观察数据.
- 用遗传方法调查潜在的因果关系.
主要方法:
- 从FAERS数据中对GLP-1RA的不良事件的不成比例分析.
- 孟德尔随机化 (MR) 使用GLP1R cis-eQTL来评估与情绪/行为障碍的联系.
- 总结数据MR (SMR) 分析以进一步评估遗传关联.
主要成果:
- 对275,718个不良事件的分析显示,在肥胖子组中,与自杀相关事件的轻微信号.
- 遗传证据表明GLP-1RA与减少焦虑,抑郁,情绪不稳定,双相情感障碍和自杀的风险有关.
- 减肥部分调解了GLP-1RA对抑郁和情绪不稳定性的影响;SMR显示与焦虑有负面关联.
结论:
- 观察和MR分析表明,GLP-1 RA治疗没有增加情绪/行为障碍的风险.
- GLP-1RA的遗传激活可能会降低焦虑,抑郁和情绪不稳定性的风险.
- 这些发现有助于更清楚地了解GLP-1RA在心理健康方面的安全性.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
857
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
857
Human Genetics
1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
774
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
774
G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K
Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559


